MicroPort Scientific Corp (0853) Fair Value & Analysis
Healthcare · HK · Market cap HK$12.2B
Fair value as of: Aug 20, 2026
From 11 valuation models · updated today
Fair value updated Aug 20, 2026, revised from HK$0.4300 to HK$4.38 (+918.6%) since Aug 13, 2026. Share price −8.6% over the past month.
Below-average quality, and screening another 32% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$5.48). The favourable scenario is already priced in.
- Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.
How to read this chart
60‑month range HK$4.56 – HK$71.66 · fair‑value band HK$3.29 – HK$5.48 · the HK$6.40 price screens above the HK$4.38 fair value. Dashed = 300-day average. As of Aug 20, 2026.
Analysis
MicroPort Scientific Corp (0853) currently trades at HK$6.40, while our model-based Fair Value estimate is HK$4.38, implying the stock looks roughly 31.6% overvalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, MicroPort Scientific Corp generated revenue of HK$1.1B at a net margin of 4.4%. Revenue grew 18.1% year over year. It earns a return on equity of 2.9%. Net debt stands at HK$918M. Fundamentals as of Aug 20, 2026
Our scenario range runs from HK$3.29 (bear case) to HK$5.48 (bull case); at HK$6.40, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 61% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -32%, 0853 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 11 models by family
Widest divergence: DCF Models (HK$1.09) versus Earnings-Based (HK$0.2800). Highest evidence: Residual Income (76).
Notify me when 0853 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 23
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, the United States of America, Europe, Middle East and Africa, Japan, and internationally.
Full company description
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, the United States of America, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; and coronary stents, related delivery systems, balloon catheters, accessories, and active devices. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma products, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers. Its Endovascular and Peripheral Vascular Devices segment provides disease solutions for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection aneurysms, and other arteriovenous related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for cerebrovascular diseases. The company's Surgical Robot Business segment offers surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Structural Heart Disease Business segment provides heart valve devices. It is also involved in the distribution of medical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
MicroPort Scientific Corp reported revenue of HK$996M in FY2025 versus HK$779M in FY2021, a compound +6.4%/yr. Reported net income was HK$48.6M in FY2025.
0853 screens 32% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 360 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | -2% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 240.60 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
| CLASSYS Inc 214150 | 39,700 KRW | 20,415 KRW | -49% |
Compare MicroPort Scientific Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is MicroPort Scientific Corp (0853) overvalued or undervalued?
What is the fair value of 0853?
What is the quality score of 0853?
What is the revenue of MicroPort Scientific Corp (0853)?
What is the net profit margin of 0853?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track MicroPort Scientific Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.